Sanofi - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 216 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Sanofi - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Sanofi - Product Pipeline Review - 2014', provides an overview of the Sanofi's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sanofi's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Sanofi including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Sanofi's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Sanofi's pipeline products

Reasons to buy

- Evaluate Sanofi's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Sanofi in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Sanofi's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Sanofi and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sanofi
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Sanofi and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Sanofi Snapshot 6
Sanofi Overview 6
Key Information 6
Key Facts 6
Sanofi - Research and Development Overview 7
Key Therapeutic Areas 7
Sanofi - Pipeline Review 14
Pipeline Products by Stage of Development 14
Pipeline Products - Monotherapy 15
Pipeline Products - Combination Treatment Modalities 16
Pipeline Products - Partnered Products 17
Pipeline Products - Out-Licensed Products 20
Sanofi - Pipeline Products Glance 22
Sanofi - Late Stage Pipeline Products 22
Sanofi - Clinical Stage Pipeline Products 25
Sanofi - Early Stage Pipeline Products 28
Sanofi - Drug Profiles 31
cabazitaxel 31
alemtuzumab 33
semuloparin 36
(fluticasone proprionate + formoterol fumarate) 37
(insulin glargine + lixisenatide) 39
diphtheria + tetanus toxoids + acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine 41
influenza virus vaccine 42
Insulin U-300 44
japanese encephalitis vaccine (live attenuated) 46
MACI 48
tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine adsorbed 49
fexinidazole 50
ferroquine 52
leflunomide 53
OZ-439 + ferroquine 55
probucol 56
SAR-100842 57
SAR-156597 58
SAR-256212 59
SAR-279356 62
SAR-292833 63
SAR-3419 64
vatelizumab 66
plerixafor 67
StarGen 69
UshStat 71
(DHA-GPL + Vit D) 73
AVE-8112 74
Biosimilar Targeting Insulin Receptor for Type 1 and Type 2 Diabetes 75
GZ-402671 76
SAR-113244 77
SAR-125844 78
SAR-164653 79
SAR-228810 80
SAR-245408 81
SAR-245408 + SAR-256212 84
SAR-245409 85
SAR-252067 87
SAR-260301 88
SAR-405838 89
SAR-405838 + pimasertib hydrochloride 90
SAR-407899 91
SAR-438151 92
SAR-566658 93
SAR-650984 95
Subunit Vaccine for H1N1 Infection 96
AVE-0991 97
AVE-3085 98
BSI-302 99
BSI-401 100
Drugs for Type 1 Diabetes 101
MI-51964 102
Monoclonal Antibody Conjugated 4 For Oncology 103
Monoclonal Antibody Conjugated 5 For Oncology 104
Monoclonal Antibody Conjugated for Solid Cancer 105
RDX-002 106
SAR-110068 107
SAR-131675 108
SAR-184841 109
SAR-224 110
SAR-244181 111
SAR-296968 112
SAR-396049 113
Small Molecules 1 for Tuberculosis 114
Small Molecules for Malaria 115
Small Molecules to Inhibit DGAT-1 for Metabolic Disorders 116
Small Molecules to Inhibit PI3K Beta for Oncology 117
Vasculotide 118
Labyrinthopeptine A1 119
Small Molecule 4 for Tuberculosis 120
Small Molecule for Calcific Aortic Valve Stenosis 121
Small Molecule for Duchenne Muscular Dystrophy 122
Small Molecules 2 For Tuberculosis 123
Small Molecules to Inhibit 11 Beta-Hydroxysteroid Dehydrogenase for Diabetes 124
Small Molecules to Inhibit Protein Kinase for Multiple Undisclosed Indications 125
Small Molecules to Inhibit Protein Kinase for Undisclosed 126
Small Molecules-3 for Tuberculosis 127
Sanofi - Pipeline Analysis 128
Sanofi - Pipeline Products by Target 128
Sanofi - Pipeline Products by Route of Administration 132
Sanofi - Pipeline Products by Molecule Type 134
Sanofi - Pipeline Products by Mechanism of Action 136
Sanofi - Recent Pipeline Updates 141
Sanofi - Dormant Projects 169
Sanofi - Discontinued Pipeline Products 178
Discontinued Pipeline Product Profiles 180
Sanofi - Company Statement 190
Sanofi - Locations And Subsidiaries 191
Head Office 191
Other Locations & Subsidiaries 191
Sanofi - Key Manufacturing Facilities 207
Appendix 208
Methodology 208
Coverage 208
Secondary Research 208
Primary Research 208
Expert Panel Validation 208
Contact Us 209
Disclaimer 209

List of Tables
Sanofi, Key Information 13
Sanofi, Key Facts 13
Sanofi - Pipeline by Indication, 2014 15
Sanofi - Pipeline by Stage of Development, 2014 21
Sanofi - Monotherapy Products in Pipeline, 2014 22
Sanofi - Combination Treatment Modalities in Pipeline, 2014 23
Sanofi - Partnered Products in Pipeline, 2014 24
Sanofi - Partnered Products/ Combination Treatment Modalities, 2014 25
Sanofi - Out-Licensed Products in Pipeline, 2014 27
Sanofi - Out-Licensed Products/ Combination Treatment Modalities, 2014 28
Sanofi - Pre-Registration, 2014 29
Sanofi - Filing rejected/Withdrawn, 2014 30
Sanofi - Phase III, 2014 31
Sanofi - Phase II, 2014 32
Sanofi - Phase I, 2014 33
Sanofi - Preclinical, 2014 35
Sanofi - Discovery, 2014 37
Sanofi - Pipeline by Target, 2014 136
Sanofi - Pipeline by Route of Administration, 2014 140
Sanofi - Pipeline by Molecule Type, 2014 142
Sanofi - Pipeline Products by Mechanism of Action, 2014 144
Sanofi - Recent Pipeline Updates, 2014 148
Sanofi - Dormant Developmental Projects,2014 176
Sanofi - Discontinued Pipeline Products, 2014 185
Sanofi, Other Locations 198
Sanofi, Subsidiaries 198
Sanofi, Key Manufacturing Facilities 214